Blog
Background Investigation Methods, Corporate Intelligence & Due Diligence, e-Discovery Techniques, Investigation & Intelligence Feeds, Judgment Enforcement, Legal Enforcement Cases, Legal Ethics & Intelligence, Legal Technology & Intelligence, Witness Credibility Analysis
Prolia® / Xgeva® Biosimilar Updates: FDA Approves Accord’s Osvyrti® / Jubereq®, Amgen and Hikma Settle BPCIA Litigation
On November 20, 2025, the FDA approved Accord’s Osvyrti® and Jubereq® (denosumab-desu), biosimilars of Amgen’s Prolia® / Xgeva® (denosumab)….
By: Venable LLP